Effectiveness and safety of rivaroxaban or low-molecular-weight heparin in non-major surgery .
Effectiveness and safety of rivaroxaban or low-molecular-weight heparin in non-major orthopedic surgery: a meta-analysis of randomized controlled trials.
J Orthop Surg Res . 2024 Sep 28;19(1):609.Five randomized controlled trials, including 5101 patients undergoing non-major orthopedic surgery, were analyzed to compare rivaroxaban with LMWH for thromboprophylaxis. Pooled outcomes of interest included venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE), overall bleeding events, and major bleeding events. The results showed no significant difference between rivaroxaban and LMWH in preventing VTE or in the incidence of bleeding events. These findings suggest that both treatments have comparable efficacy and safety profiles for patients undergoing non-major orthopedic surgery.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
